Advertisement

Topics

With Bristol-Myers Squibb Buyout on the Horizon, Celgene Continues Business as Usual

20:00 EDT 25 Mar 2019 | BioSpace

Today, Celgene submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its ozanimod for adults with relapsing forms of multiple sclerosis (RMS).

Original Article: With Bristol-Myers Squibb Buyout on the Horizon, Celgene Continues Business as Usual

NEXT ARTICLE

More From BioPortfolio on "With Bristol-Myers Squibb Buyout on the Horizon, Celgene Continues Business as Usual"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...